CA2169173A1 - Methods for stimulating erythropoiesis using thrombopoietin - Google Patents

Methods for stimulating erythropoiesis using thrombopoietin

Info

Publication number
CA2169173A1
CA2169173A1 CA002169173A CA2169173A CA2169173A1 CA 2169173 A1 CA2169173 A1 CA 2169173A1 CA 002169173 A CA002169173 A CA 002169173A CA 2169173 A CA2169173 A CA 2169173A CA 2169173 A1 CA2169173 A1 CA 2169173A1
Authority
CA
Canada
Prior art keywords
methods
thrombopoietin
stimulating erythropoiesis
erythropoiesis
erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002169173A
Other languages
French (fr)
Other versions
CA2169173C (en
Inventor
Kenneth Kaushansky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
Kenneth Kaushansky
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Kaushansky, University Of Washington filed Critical Kenneth Kaushansky
Publication of CA2169173A1 publication Critical patent/CA2169173A1/en
Application granted granted Critical
Publication of CA2169173C publication Critical patent/CA2169173C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Abstract

Methods for stimulating erythropoiesis using thrombopoietin and erythropoietin are provided. The methods provided may be used to stimulate erythropoiesis in bone marrow and peripheral blood cells and in vitro and in vivo. In addition, methods for treatment of thrombocytopenia and anemia in patients are disclosed using thrombopoietin and erythropoietin.
CA002169173A 1994-02-14 1995-02-09 Methods for stimulating erythropoiesis using thrombopoietin Expired - Fee Related CA2169173C (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US19602594A 1994-02-14 1994-02-14
US08/196,025 1994-02-14
US20319794A 1994-02-25 1994-02-25
US08/203,197 1994-02-25
US21520394A 1994-03-21 1994-03-21
US08/215,203 1994-03-21
US25249194A 1994-06-01 1994-06-01
US08/252,491 1994-06-01
US28841794A 1994-08-09 1994-08-09
US08/288,417 1994-08-09
US33556694A 1994-11-07 1994-11-07
US08/335,566 1994-11-07
US34774894A 1994-12-01 1994-12-01
US08/347,748 1994-12-01
PCT/US1995/001829 WO1995021626A1 (en) 1994-02-14 1995-02-09 Methods for stimulating erythropoiesis using thrombopoietin

Publications (2)

Publication Number Publication Date
CA2169173A1 true CA2169173A1 (en) 1995-08-17
CA2169173C CA2169173C (en) 2002-10-15

Family

ID=27569260

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002169173A Expired - Fee Related CA2169173C (en) 1994-02-14 1995-02-09 Methods for stimulating erythropoiesis using thrombopoietin

Country Status (6)

Country Link
EP (1) EP0723456A1 (en)
AU (1) AU1843595A (en)
CA (1) CA2169173C (en)
FI (1) FI960930A0 (en)
NZ (1) NZ281482A (en)
WO (1) WO1995021626A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6316254B1 (en) * 1994-02-14 2001-11-13 University Of Washington Methods for stimulating erythropoiesis using hematopoietic proteins
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
DK0885242T3 (en) 1995-06-07 2008-07-14 Glaxo Group Ltd Peptides and compounds that bind to a thrombopoietin receptor
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
WO2002015926A1 (en) * 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha c-mpl LIGAND-CONTAINING MEDICINAL COMPOSITIONS FOR INCREASING PLATELETS AND ERYTHROCYTES
CA2499625A1 (en) 2002-09-18 2004-04-01 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
MXPA06002292A (en) 2003-08-28 2006-09-04 Johnson & Johnson Peptides and compounds that bind to thrombopoietin receptors.
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
CA2642389C (en) * 2006-02-14 2014-05-06 Janssen Pharmaceutica N.V. Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia

Also Published As

Publication number Publication date
WO1995021626A1 (en) 1995-08-17
NZ281482A (en) 2000-09-29
AU1843595A (en) 1995-08-29
CA2169173C (en) 2002-10-15
FI960930A (en) 1996-02-28
FI960930A0 (en) 1996-02-28
EP0723456A1 (en) 1996-07-31

Similar Documents

Publication Publication Date Title
CA2169173A1 (en) Methods for stimulating erythropoiesis using thrombopoietin
AU6780687A (en) Benzamido-aromatic derivatives, process for their preparation and their use in human or veterinary medicine and in cosmetics
DE69718053T2 (en) in vitro methods and use of pharmaceutical compositions for the treatment of inner ear hair cells
CA2131168A1 (en) Decontaminating blood components
CA2276180A1 (en) Method for activating human antigen-presenting cells, activated human antigen-presenting cells, and use thereof
CZ200151A3 (en) Sulfur-substituted N-arylamides of sulfonylaminocarboxylic acid, process of their preparation, their use and pharmaceutical preparations in which they are comprised
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
WO1996015758A3 (en) Methods for stimulating erythropoiesis using thrombopoietin
AU586920B2 (en) Aromatic compounds process for their preparation, and their use in human and veterinary medicine and in cosmetics
HUP0301030A3 (en) New azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
HU9802577D0 (en) In vivo dyeing material, process for producing thereof and use for identifying of living tissues
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
ITRM970238A0 (en) USE OF THE NERVE GROWTH FACTOR IN THE PRESERVATION OF CORNEAS IN CULTURE, IN THE PRODUCTION OF CORNEAL AND CONJUNCTIVAL TISSUES IN VITRO AND IN THE THERAPY OF CORNEAL AND CONJUNCTIVAL DISEASES
CA2319542A1 (en) The treatment of sexual dysfunction in certain patient groups
EP0588477A3 (en) Medicinal composition comprising tcf-ii
AU7926487A (en) Apparatus for effect-field treatment matched with the human body's frequency spectrum and their production method
AU3255295A (en) Hybrid molecules useful in the treatment of tumors, their preparation and use in pharmaceutical compositions
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
CA2305764A1 (en) Bile acid salts of metals with physiological action and the use thereof in therapy
IL97801A0 (en) Oligonucleotides,methods for in vitro tissue cell culture using the same and cosmetic compositions containing the same
EP0668771A4 (en) Treatment of autoimmune diseases by inducing tolerance to cells, tissues and organs.
AU5448490A (en) Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
UA23999C2 (en) A process for preparation of agent “bipex” for the treatment of neurooncologic diseases
DE69023331T2 (en) TREATED HEMOGLOBIN AND THEIR PRODUCTION.
AU5875599A (en) Polymorphisms in the human vcam-1 gene, suitable for diagnosis and treatment of vcam-1 ligand mediated diseases

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed